activin-receptor-type-1-activin-receptor-like-kinase-2-or-serine2Fthreonine-protein-kinase-receptor-r1-or-tgf-b-superfamily-receptor-type-i-or-alk2-or-acvr1-or-ec-271130---pipeline-review-h2-2016-24marketreports
This report provided by 24 market reports is about,, ‘Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016’, provides in depth analysis on Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted pipeline therapeutics.
This report provided by 24 market reports is about,, ‘Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) - Pipeline Review, H2 2016’, provides in depth analysis on Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted pipeline therapeutics.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Rep<strong>or</strong>t Title:<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like<br />
Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I<br />
<strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) - Pipeline<br />
Review, H2 <strong>2016</strong><br />
Published On:<br />
Pages: 35<br />
Categ<strong>or</strong>y: Life Sciences<br />
Rep<strong>or</strong>t Overview:<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) -<br />
Pipeline Review, H2 <strong>2016</strong> Summary Global Markets Dir<strong>ec</strong>t’s, ‘Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin<br />
R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily<br />
R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) - Pipeline Review, H2 <strong>2016</strong>’, provides in<br />
depth analysis on Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine<br />
Protein Kinase R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC<br />
2.7.11.30) targeted <strong>pipeline</strong> therapeutics. The rep<strong>or</strong>t provides comprehensive inf<strong>or</strong>mation on<br />
the Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein<br />
Kinase R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30),<br />
targeted therapeutics, complete with analysis by indications, stage of development, m<strong>ec</strong>hanism<br />
of action (MoA), route of administration (RoA) and mol<strong>ec</strong>ule <strong>type</strong>. The rep<strong>or</strong>t also covers the<br />
descriptive pharmacological action of the therapeutics, its complete research and development<br />
hist<strong>or</strong>y and latest news and press releases. Additionally, the rep<strong>or</strong>t provides an overview of key<br />
players involved in Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong><br />
Serine/Threonine Protein Kinase R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2<br />
<strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) targeted therapeutics development and features d<strong>or</strong>mant and<br />
discontinued proj<strong>ec</strong>ts. Global Markets Dir<strong>ec</strong>t’s rep<strong>or</strong>t features investigational drugs from<br />
across globe covering over 20 therapy areas and nearly 3,000 indications. The rep<strong>or</strong>t is built<br />
using data and inf<strong>or</strong>mation sourced from Global Markets Dir<strong>ec</strong>t’s proprietary databases,<br />
company/university websites, clinical trial registries, conferences, SEC filings, invest<strong>or</strong><br />
presentations and featured press releases from company/university sites and industry-sp<strong>ec</strong>ific<br />
third party sources. Drug profiles featured in the rep<strong>or</strong>t undergoes periodic <strong>review</strong> following a<br />
stringent set of processes to ensure that all the profiles are updated with the latest set of<br />
inf<strong>or</strong>mation. Additionally, various dynamic tracking processes ensure that the most r<strong>ec</strong>ent<br />
24marketrep<strong>or</strong>ts | International +1 646 781 7170 | www.24marketrep<strong>or</strong>ts.com
developments are captured on a real time basis. The rep<strong>or</strong>t helps in identifying and tracking<br />
emerging players in the market and their p<strong>or</strong>tfolios, enhances d<strong>ec</strong>ision making capabilities and<br />
helps to create eff<strong>ec</strong>tive counter strategies to gain competitive advantage. Note: *Certain<br />
s<strong>ec</strong>tions in the rep<strong>or</strong>t may be removed <strong>or</strong> altered based on the availability and relevance of<br />
data. *Updated rep<strong>or</strong>t will be delivered in 48 hours of <strong>or</strong>der confirmation. Scope - The rep<strong>or</strong>t<br />
provides a snapshot of the global therapeutic landscape f<strong>or</strong> Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin<br />
R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily<br />
R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) - The rep<strong>or</strong>t <strong>review</strong>s Activin R<strong>ec</strong>ept<strong>or</strong><br />
Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF<br />
B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) targeted therapeutics<br />
under development by companies and universities/research institutes based on inf<strong>or</strong>mation<br />
derived from company and industry-sp<strong>ec</strong>ific sources - The rep<strong>or</strong>t covers <strong>pipeline</strong> products<br />
based on various stages of development ranging from pre-registration till discovery and<br />
undisclosed stages - The rep<strong>or</strong>t features descriptive drug profiles f<strong>or</strong> the <strong>pipeline</strong> products<br />
which includes, product description, descriptive MoA, R&D brief, licensing and collab<strong>or</strong>ation<br />
details & other developmental activities - The rep<strong>or</strong>t <strong>review</strong>s key players involved in Activin<br />
R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase R<strong>ec</strong>ept<strong>or</strong><br />
R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) targeted<br />
therapeutics and enlists all their maj<strong>or</strong> and min<strong>or</strong> proj<strong>ec</strong>ts - The rep<strong>or</strong>t assesses Activin<br />
R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase R<strong>ec</strong>ept<strong>or</strong><br />
R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) targeted<br />
therapeutics based on m<strong>ec</strong>hanism of action (MoA), route of administration (RoA) and mol<strong>ec</strong>ule<br />
<strong>type</strong> - The rep<strong>or</strong>t summarizes all the d<strong>or</strong>mant and discontinued <strong>pipeline</strong> proj<strong>ec</strong>ts - The rep<strong>or</strong>t<br />
<strong>review</strong>s latest news and deals related to Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase<br />
2 <strong>or</strong> Serine/Threonine Protein Kinase R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong><br />
ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) targeted therapeutics Reasons to buy - Gain strategically<br />
significant competit<strong>or</strong> inf<strong>or</strong>mation, analysis, and insights to f<strong>or</strong>mulate eff<strong>ec</strong>tive R&D strategies<br />
- Identify emerging players with potentially strong product p<strong>or</strong>tfolio and create eff<strong>ec</strong>tive<br />
counter-strategies to gain competitive advantage - Identify and understand the targeted<br />
therapy areas and indications f<strong>or</strong> Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong><br />
Serine/Threonine Protein Kinase R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2<br />
<strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) - Identify the use of drugs f<strong>or</strong> target identification and drug<br />
repurposing - Identify potential new clients <strong>or</strong> partners in the target demographic - Develop<br />
strategic initiatives by understanding the focus areas of leading companies - Plan mergers and<br />
acquisitions eff<strong>ec</strong>tively by identifying key players and it’s most promising <strong>pipeline</strong> therapeutics<br />
- Devise c<strong>or</strong>r<strong>ec</strong>tive measures f<strong>or</strong> <strong>pipeline</strong> proj<strong>ec</strong>ts by understanding Activin R<strong>ec</strong>ept<strong>or</strong> Type 1<br />
(Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B<br />
Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) development landscape -<br />
Develop and design in-licensing and out-licensing strategies by identifying prosp<strong>ec</strong>tive<br />
partners with the most attractive proj<strong>ec</strong>ts to enhance and expand business potential and scope<br />
24marketrep<strong>or</strong>ts | International +1 646 781 7170 | www.24marketrep<strong>or</strong>ts.com
Table of Contents:<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 4<br />
List of Figures 4<br />
Introduction 5<br />
Global Markets Dir<strong>ec</strong>t Rep<strong>or</strong>t Coverage 5<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30)<br />
Overview 6<br />
Therapeutics Development 7<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) -<br />
Products under Development by Stage of Development 7<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) -<br />
Products under Development by Therapy Area 8<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) -<br />
Products under Development by Indication 9<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) -<br />
Pipeline Products Glance 10<br />
Early Stage Products 10<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) -<br />
Products under Development by Companies 11<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) -<br />
Therapeutics Assessment 13<br />
Assessment by Monotherapy/Combination Products 13<br />
Assessment by M<strong>ec</strong>hanism of Action 14<br />
Assessment by Route of Administration 15<br />
Assessment by Mol<strong>ec</strong>ule Type 17<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) -<br />
Companies Involved in Therapeutics Development 19<br />
La Jolla Pharmaceutical Company 19<br />
Tolero Pharmaceuticals, Inc. 20<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) - Drug<br />
Profiles 21<br />
LJPC-6417 - Drug Profile 21<br />
Product Description 21<br />
24marketrep<strong>or</strong>ts | International +1 646 781 7170 | www.24marketrep<strong>or</strong>ts.com
M<strong>ec</strong>hanism Of Action 21<br />
R&D Progress 21<br />
Small Mol<strong>ec</strong>ule 1 To Inhibit ALK2 f<strong>or</strong> Fibrodysplasia Ossificans Progressiva - Drug Profile 22<br />
Product Description 22<br />
M<strong>ec</strong>hanism Of Action 22<br />
R&D Progress 22<br />
Small Mol<strong>ec</strong>ule 2 To Inhibit ALK2 f<strong>or</strong> Fibrodysplasia Ossificans Progressiva - Drug Profile 23<br />
Product Description 23<br />
M<strong>ec</strong>hanism Of Action 23<br />
R&D Progress 23<br />
Synthetic Peptides to Antagonize TGF-Beta R<strong>ec</strong>ept<strong>or</strong> f<strong>or</strong> Diabetic Foot Ulcers, Pulmonary<br />
Fibrosis and Dermatology - Drug Profile 24<br />
Product Description 24<br />
M<strong>ec</strong>hanism Of Action 24<br />
R&D Progress 24<br />
TP-0184 - Drug Profile 26<br />
Product Description 26<br />
M<strong>ec</strong>hanism Of Action 26<br />
R&D Progress 26<br />
TP-0413 - Drug Profile 27<br />
Product Description 27<br />
M<strong>ec</strong>hanism Of Action 27<br />
R&D Progress 27<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) -<br />
D<strong>or</strong>mant Proj<strong>ec</strong>ts 28<br />
Activin R<strong>ec</strong>ept<strong>or</strong> Type 1 (Activin R<strong>ec</strong>ept<strong>or</strong> Like Kinase 2 <strong>or</strong> Serine/Threonine Protein Kinase<br />
R<strong>ec</strong>ept<strong>or</strong> R1 <strong>or</strong> TGF B Superfamily R<strong>ec</strong>ept<strong>or</strong> Type I <strong>or</strong> ALK2 <strong>or</strong> ACVR1 <strong>or</strong> EC 2.7.11.30) -<br />
Featured News & Press Releases 29<br />
D<strong>ec</strong> 07, 2015: Tolero Pharmaceuticals Presents Positive Pr<strong>ec</strong>linical Data on Hepcidin Inhibition<br />
f<strong>or</strong> the Treatment of Anemia Associated with Chronic Disease 29<br />
Nov 12, 2015: Tolero Pharmaceuticals Presents Positive Clinical and Pr<strong>ec</strong>linical Data on<br />
TP-0184 in Leukemia and Anemia at the 57th ASH Annual Meeting and Exposition 29<br />
Aug 18, 2015: La Jolla Pharmaceutical Company R<strong>ec</strong>eives Orphan Drug Designation f<strong>or</strong> Two<br />
Novel Compounds f<strong>or</strong> Fibrodysplasia Ossificans Progressiva 30<br />
Jun 16, 2015: Tolero Pharmaceuticals Presents Positive Pr<strong>ec</strong>linical Data on Hepcidin Inhibition<br />
f<strong>or</strong> the Treatment of Anemia Associated with Chronic Disease 30<br />
Jun 04, 2015: Tolero Pharmaceuticals to Present Pr<strong>ec</strong>linical Pipeline Data On TP-0184 at the<br />
20th Congress of European Hematology Association, EHA 31<br />
Apr 18, 2013: La Jolla Pharma R<strong>ec</strong>eives Orphan Designation From FDA F<strong>or</strong> LJPC-6417 31<br />
Sep 14, 2012: Tolero Pharma R<strong>ec</strong>eives Small Business Innovation Research Contract From<br />
National Cancer Institute 32<br />
Nov 16, 2011: H<strong>or</strong>mone That Controls Iron Levels May Be Target f<strong>or</strong> Atherosclerosis<br />
Treatment 32<br />
Appendix 34<br />
Methodology 34<br />
24marketrep<strong>or</strong>ts | International +1 646 781 7170 | www.24marketrep<strong>or</strong>ts.com
Coverage 34<br />
S<strong>ec</strong>ondary Research 34<br />
Primary Research 34<br />
Expert Panel Validation 34<br />
Contact Us 34<br />
Disclaimer 35<br />
Get M<strong>or</strong>e Inf<strong>or</strong>mation about the Rep<strong>or</strong>t:<br />
Rep<strong>or</strong>t URL:<br />
https://www.24marketrep<strong>or</strong>ts.com/mr-admin/life-sciences/<strong>activin</strong>-<strong>r<strong>ec</strong>ept<strong>or</strong></strong>-<strong>type</strong>-1-<strong>activin</strong>-r<strong>ec</strong>ept<br />
<strong>or</strong>-<strong>like</strong>-<strong>kinase</strong>-2-<strong>or</strong>-<strong>serine2Fthreonine</strong>-<strong>protein</strong>-<strong>kinase</strong>-<strong>r<strong>ec</strong>ept<strong>or</strong></strong>-<strong>r1</strong>-<strong>or</strong>-<strong>tgf</strong>-b-<strong>superfamily</strong>-<strong>r<strong>ec</strong>ept<strong>or</strong></strong><strong>type</strong>-i-<strong>or</strong>-<strong>alk2</strong>-<strong>or</strong>-acv<strong>r1</strong>-<strong>or</strong>-<strong>ec</strong>-<strong>271130</strong>---<strong>pipeline</strong>-<strong>review</strong>-<strong>h2</strong>-<strong>2016</strong><br />
To get Rep<strong>or</strong>t Sample:<br />
https://www.24marketrep<strong>or</strong>ts.com/mr-admin/request-sample/<strong>activin</strong>-<strong>r<strong>ec</strong>ept<strong>or</strong></strong>-<strong>type</strong>-1-<strong>activin</strong>-r<strong>ec</strong><br />
ept<strong>or</strong>-<strong>like</strong>-<strong>kinase</strong>-2-<strong>or</strong>-<strong>serine2Fthreonine</strong>-<strong>protein</strong>-<strong>kinase</strong>-<strong>r<strong>ec</strong>ept<strong>or</strong></strong>-<strong>r1</strong>-<strong>or</strong>-<strong>tgf</strong>-b-<strong>superfamily</strong><strong>r<strong>ec</strong>ept<strong>or</strong></strong>-<strong>type</strong>-i-<strong>or</strong>-<strong>alk2</strong>-<strong>or</strong>-acv<strong>r1</strong>-<strong>or</strong>-<strong>ec</strong>-<strong>271130</strong>---<strong>pipeline</strong>-<strong>review</strong>-<strong>h2</strong>-<strong>2016</strong><br />
24marketrep<strong>or</strong>ts | International +1 646 781 7170 | www.24marketrep<strong>or</strong>ts.com
Change language